Moderna shares climb over 150% as mRNA vaccine with Merck succeeds in large trial for skin cancer
The study is still ongoing, but interim results showed that the treatment, Intismeran, met its primary endpoint of reducing the risk of cancer recurrence
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Wow
0
Sad
0
Angry
0
Comments (0)